Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11400185 | 0.84 | KDM4E (0.68) | KDM4ESLC2A1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL28568179 | 0.81 | KDM4E (1.00) | KDM4ESLC2A1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL31548610 | 0.80 | KDM4E (0.62) | KDM4ESLC2A1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL3901331 | 0.77 | AR (0.44) | KDM4EALDH1A1MAPTHTTLMNA | |
| SCHEMBL20552496 | 0.77 | AR (0.44) | KDM4EALDH1A1MAPTHTTLMNA | |
| SCHEMBL27596879 | 0.74 | KDM4E (0.58) | KDM4ESLC2A1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL27579097 | 0.74 | KDM4E (0.58) | KDM4ESLC2A1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL7921954 | 0.72 | ATM (0.61) | KDM4EALDH1A1CYP3A4ATMSMN1; SMN2 | |
| SCHEMBL28436076 | 0.71 | KDM4E (0.43) | KDM4ECYP3A4ATMLMNA | |
| SCHEMBL6584591 | 0.71 | MAPT (0.46) | KDM4EALDH1A1CYP3A4SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2195322-B1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2195322-B1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Merck Patent Gesellschaft Beschrankter Haftung (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Merck Patent Gesellschaft Beschrankter Haftung (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Merck Patent Gesellschaft Beschrankter Haftung (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-2195322-A1 | IMIDAZOÝ1,2-A¨PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | Merck Patent GmbH (DE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009049731-A1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009049731-A1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | TYMS, CCNT1, INSR | KDM4E 3197/4885SLC2A1 289/4885ALDH1A1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.